Ovarian Cancer | Specialty

The OncLive Ovarian Cancer condition center page is a comprehensive resource for clinical news and expert insights on ovarian cancer and evolving treatment approaches, including PARP inhibitors, antibody-drug conjugates, chemotherapy and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in ovarian cancer.

Expert Discusses Promise of Checkpoint Inhibitors in Ovarian Cancer

November 21st 2017

Jonathan Ledermann, MD, discusses the promise of immunotherapy in ovarian cancer and emphasized the importance of participation in clinical trials.

Dr. Leitao on the Benefits of Surgery in Ovarian Cancer

November 21st 2017

Mario M. Leitao Jr, MD, FACOG, FACS, fellowship director, gynecology service, director, Minimal Access and Robotic Surgery Program, Department of Surgery, Memorial Sloan Kettering Cancer Center, discusses the importance of surgery for patients with ovarian cancer.

The Future Role of PARP Inhibition in Ovarian Cancer

November 20th 2017

Combinations With PARP Inhibitors for Ovarian Cancer

November 20th 2017

Ovarian Cancer: Selecting an Appropriate PARP Inhibitor

November 20th 2017

Ovarian Cancer: Treating Through Multiple Progressions

November 20th 2017

Ovarian Cancer: Comparisons Between PARP Inhibitors

November 20th 2017

PARP Inhibitors's Role as Maintenance Therapy in EOC

November 20th 2017

Ovarian Cancer: Optimizing Treatment With Niraparib

November 20th 2017

Treating Ovarian Cancer With Niraparib: The NOVA Trial

November 20th 2017

Platinum-Sensitive Relapsed Ovarian Cancer: Rucaparib

November 20th 2017

Value of Olaparib in BRCA-Mutated Advanced Ovarian Cancer

November 20th 2017

PARP Inhibitors' Impact on Advanced Ovarian Cancer

November 20th 2017

Ovarian Cancer: Considerations for Molecular Testing

November 20th 2017

Ovarian Cancer: Testing for Mutations

November 20th 2017

Molecular Testing in Ovarian Cancer

November 20th 2017

Dr. Markman on Endpoints in Clinical Trials for Ovarian Cancer

November 16th 2017

Maurie Markman, MD, president of medicine and science, Cancer Treatment Centers of America, editor-in-chief, OncologyLive, discusses endpoints in clinical trials for ovarian cancer.

Dr. Ledermann on Rucaparib Maintenance in Ovarian Cancer

November 16th 2017

Jonathan Ledermann, MD, professor of medical oncology, UCL Cancer Institute, London, United Kingdom, discusses rucaparib (Rubraca) maintenance in ovarian cancer.

Soft Tissue Sarcoma: An Increasing Number of Options

November 14th 2017

Second-Line Therapy Options: Role of Trabectedin

November 14th 2017